nach oben

Supportive Care in Cancer

Erschienen in:

08.05.2017 | Review Article

The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review

verfasst von: Gary H. Lyman, Kim Allcott, Jacob Garcia, Scott Stryker, Yanli Li, Maureen T. Reiner, Derek Weycker

Erschienen in: Supportive Care in Cancer | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Granulocyte colony-stimulating factors (G-CSF) are commonly used in clinical practice to prevent febrile neutropenia (FN). US and EU prescribing information and treatment guidelines from the NCCN, ASCO, and EORTC specify that pegfilgrastim, a long-acting (LA) G-CSF, should be administered at least 24 h after myelosuppressive chemotherapy. Nevertheless, many patients receive LA G-CSFs on the same day as chemotherapy. This systematic literature review evaluated the relative merits of same-day versus next-day dosing of LA G-CSFs.

Methods

A broad Ovid MEDLINE® and Embase® literature search was conducted that examined all publications indexed before May 9, 2016 that compared same-day versus next-day LA G-CSF administration. A congress abstract literature search included congresses from January 1, 2011 to April 6, 2016. The parameters for this review were prospectively delineated in a research protocol and adhered to the PRISMA Guidelines.

Results

The first part of the systematic literature search identified 1736 publications. After elimination of duplicates, title/abstract screening was conducted on 1440 records, and full text review was conducted on 449 publications. Eleven publications met all criteria and are included in this systematic review; of these, four included data from randomized or single arm prospective studies, and seven were retrospective studies. In most studies included in this review and across a variety of tumor types, administration of pegfilgrastim at least 24 h after myelosuppressive chemotherapy resulted in improved patient outcomes.

Conclusions

Data from multiple publications support administration of pegfilgrastim at least 1 day after chemotherapy.

Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64(2):328–340CrossRefPubMed

National Cancer Institute Common Terminology Criteria for Adverse Events v4.0. (2009) NCI, NIH, DHHS. NIH publication # 09–7473.

de Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F (2010) Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol 21(Suppl 5):v252–v256CrossRefPubMed

Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I et al (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325(3):164–170CrossRefPubMed

Cohen AM, Zsebo KM, Inoue H, Hines D, Boone TC, Chazin VR et al (1987) In vivo stimulation of granulopoiesis by recombinant human granulocyte colony-stimulating factor. Proc Natl Acad Sci USA 84(8):2484–2488CrossRefPubMedPubMedCentral

Amgen (2016) NEUPOGEN® (filgrastim) Prescribing Information

Morstyn G, Foote MA, Walker T, Molineux G (2001) Filgrastim (r-metHuG-CSF) in the 21st century: SD/01. Acta Haematol 105(3):151–155CrossRefPubMed

Molineux G (2003) Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients. Anti-Cancer Drugs 14(4):259–264CrossRefPubMed

Kourlaba G, Dimopoulos MA, Pectasides D, Skarlos DV, Gogas H, Pentheroudakis G et al (2015) Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer. Support Care Cancer 23(7):2045–2051CrossRefPubMed

10.

Naeim A, Henk HJ, Becker L, Chia V, Badre S, Li X et al (2013) Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer 13:11CrossRefPubMedPubMedCentral

11.

Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G (2007) Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 23(9):2283–2295CrossRefPubMed

12.

Amgen (2015) NEULASTA® (pegfilgrastim) Prescribing Information

13.

Weycker D, Wu H, Hagiwara M, Li X, Barron RL (2014) Use of chemotherapy and same-day pegfilgrastim prophylaxis in US clinical practice. Blood 124 (21):4825

14.

Amgen (2015) NEULASTA® (pegfilgrastim) Summary of Product Characteristics European Medicines Agency

15.

Meropol NJ, Miller LL, Korn EL, Braitman LE, MacDermott ML, Schuchter LM (1992) Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst 84(15):1201–1203CrossRefPubMed

16.

Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33(28):3199–3212

17.

NCCN (2015) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Myeloid Growth Factors Version 1.2015.

18.

Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8–32CrossRefPubMed

19.

Whitworth JM, Matthews KS, Shipman KA, Numnum TM, Kendrick JE, Kilgore LC et al (2009) The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. Gynecol Oncol 112(3):601–604CrossRefPubMed

20.

Stephens JM, Li X, Reiner M, Tzivelekis S (2016) Annual patient and caregiver burden of oncology clinic visits for granulocyte-colony stimulating factor therapy in the US. J Med Econ 19(5):537–547CrossRefPubMed

21.

Weycker D, Li X, Figueredo J, Barron R, Tzivelekis S, Hagiwara M (2016) Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter? Support Care Cancer 24(5):2309–2316CrossRefPubMed

22.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6(7):e1000100CrossRefPubMedPubMedCentral

23.

Burris HA, Belani CP, Kaufman PA, Gordon AN, Schwartzberg LS, Paroly WS et al (2010) Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-Hodgkin’s lymphoma: results of four multicenter, double-blind, randomized phase II studies. J Oncol Pract 6(3):133–140CrossRefPubMedPubMedCentral

24.

Li Y, Klippel Z, Shih X, Wang H, Reiner M, Page JH (2016) Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy. Cancer Chemother Pharmacol 77(4):703–712

25.

Pagliaro LC, Munsell M, Harris D, Carolla RL, Siefker-Radtke AO (2011) Gemcitabine, paclitaxel, and doxorubicin for patients (pts) with urothelial carcinoma (UC) and renal insufficiency: Preliminary results of a multicenter phase II study. J Clin Oncol 29 (7_suppl):246

26.

Siefker-Radtke AO, Campbell MT, Munsell MF, Harris DR, Carolla RL, Pagliaro LC (2016) Front-line treatment with gemcitabine, paclitaxel, and doxorubicin for patients with Unresectable or metastatic urothelial cancer and poor renal function: final results from a phase II study. Urology 89:83–89CrossRefPubMed

27.

Billingsley CC, Jacobson SN, Crafton SM, Crim AK, Li Q, Hade EM et al (2015) Evaluation of the hematologic safety of same day versus standard administration (24- to 72-hour delay) of pegfilgrastim in gynecology oncology patients undergoing cytotoxic chemotherapy. Int J Gynecol Cancer 25(7):1331–1336CrossRefPubMed

28.

Cheng C, Gallagher EM, Yeh JY, Earl MA (2014) Rates of febrile neutropenia with pegfilgrastim on same day versus next day of CHOP with or without rituximab. Anti-Cancer Drugs 25(8):964–969CrossRefPubMed

29.

Ibrahim Z, Hughes J, McQuillan A, Baker R, Powell A, Peter M et al (2011) The effect of pegylated granulocyte-colony stimulating factor (GCSF; Pegfilgrastim, neulasta ) administration timing in relation to the chop or choplike regimen administration timing in non-hodgkin’s lymphoma (NHL) patients on development of neutropenia. Asia Pac J Clin Oncol 7:135–136

30.

Karol J, Rybicki L, Sweetenham J, Smith MR, Hill BT, Pohlman B et al. (2013) Similar incidence of febrile neutropenia with same-day versus subsequent day G-CSF administration in non-hodgkin lymphoma patients receiving R-CHOP chemotherapy. Blood 122(21):4357

31.

Linot B, Augereau P, Breheret R, Laccourreye L, Capitain O (2014) Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study. Support Care Cancer 22(10):2831–2837CrossRefPubMed

32.

Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P et al (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14(1):29–35CrossRefPubMed

33.

Holmes FA, O’Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M et al (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20(3):727–731CrossRefPubMed

34.

Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23(6):1178–1184CrossRefPubMed

Titel: The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review
verfasst von: Gary H. Lyman
Kim Allcott
Jacob Garcia
Scott Stryker
Yanli Li
Maureen T. Reiner
Derek Weycker
Publikationsdatum: 08.05.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 8/2017
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-017-3703-y

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2017

Erratum to: Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group

Self-report of symptoms in children with cancer younger than 8 years of age: a systematic review

Palliative care should be extended to the intensive care unit cancer patients

The value of the new scoring system for predicting neoplastic pericarditis in the patients with large pericardial effusion

“My choice”: breast cancer patients recollect doctors fertility preservation recommendations

Physical function and health-related quality of life in patients undergoing surgical treatment for malignant pleural mesothelioma

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie